PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising results from two groundbreaking publications on its investigational ...
Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...
The human body wasn’t designed to handle the relentless stress of modern life, yet millions of people are unknowingly trapped in a state of chronic physiological arousal that’s wreaking havoc on their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback